Condition: IgA Nephropathy · Sponsor: Calliditas Therapeutics AB
The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO® 16 mg once daily treatment in real-world clinical practice. The main question it aims to answer is: Is there a treatment benefit of TARPEYO® 16 mg QD extended use? Participants will * take part in this study for about 19 months * Have urine tests done * Have blood samples taken * Have physical examinations done
This description comes directly from the study's public registry record.
Annette LeBlanc-Donahue · 844-442-0011 · medical.information@calliditas.com
Always discuss trial participation with your own doctor first.
| Univ of Alabama/Birmingham | Birmingham, Alabama, United States | Recruiting |
| Arizona Kidney Disease & Hypertension Centers (AKDHC) | Glendale, Arizona, United States | Recruiting |
| The Medical Research Group, Inc. | Fresno, California, United States | Recruiting |
| UCI Health-UCI Medical Center | Orange, California, United States | Recruiting |
| Loma Linda University | San Bernardino, California, United States | Recruiting |
| UCSF Health-UCSF Medical Center-Parnassus - Nephrology and Hypertension Faculty Practice | San Francisco, California, United States | Recruiting |
| Stanford University | Stanford, California, United States | Recruiting |
| University of Colorado Hospital (UCH) - Kidney Disease and Hypertension Clinic - Anschutz Medical Campus Location | Aurora, Colorado, United States | Recruiting |
| Yale University Nephrology Clinical Trials Program | New Haven, Connecticut, United States | Recruiting |
| Florida Kidney Physicians | Boca Raton, Florida, United States | Recruiting |
| Central Florida Kidney Specialists | Orlando, Florida, United States | Recruiting |
| Southeastern Clinical Research Institute, LLC | Augusta, Georgia, United States | Recruiting |
+ 26 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06712407